Analysts Offer Predictions for NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at Brookline Capital Acquisition issued their Q1 2026 EPS estimates for shares of Intellia Therapeutics in a report issued on Thursday, February 26th. Brookline Capital Acquisition analyst L. Cann forecasts that the company will post earnings per share of ($0.85) for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Acquisition also issued estimates for Intellia Therapeutics’ Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.53) EPS, FY2028 earnings at $17.06 EPS and FY2029 earnings at $46.29 EPS.

A number of other research firms have also recently issued reports on NTLA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, January 22nd. Robert W. Baird set a $7.00 price target on Intellia Therapeutics in a report on Tuesday, January 27th. Oppenheimer set a $27.00 price objective on shares of Intellia Therapeutics in a research report on Friday, November 7th. JPMorgan Chase & Co. reissued an “underweight” rating and issued a $5.00 price objective (down from $12.00) on shares of Intellia Therapeutics in a research report on Friday, November 7th. Finally, KeyCorp set a $25.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, January 28th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $17.90.

Intellia Therapeutics Stock Down 3.5%

Shares of NASDAQ NTLA opened at $13.78 on Friday. The business’s 50 day moving average price is $11.89 and its two-hundred day moving average price is $13.02. The company has a market cap of $1.60 billion, a PE ratio of -3.60 and a beta of 2.10. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 55.36%. The company had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. During the same period in the prior year, the firm earned ($1.27) EPS. Intellia Therapeutics’s quarterly revenue was up 78.4% compared to the same quarter last year.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Contrarius Group Holdings Ltd increased its stake in Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after acquiring an additional 4,337,428 shares during the period. ARK Investment Management LLC grew its holdings in shares of Intellia Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after purchasing an additional 2,288,146 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock worth $116,960,000 after purchasing an additional 1,965,181 shares during the period. State Street Corp raised its stake in Intellia Therapeutics by 29.1% in the fourth quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after purchasing an additional 1,447,967 shares in the last quarter. Finally, Jupiter Asset Management Ltd. acquired a new position in Intellia Therapeutics in the third quarter valued at about $23,519,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares in the company, valued at $907,488.93. This represents a 7.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the transaction, the executive vice president directly owned 101,528 shares in the company, valued at $935,072.88. This represents a 9.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 53,051 shares of company stock worth $488,600. Corporate insiders own 3.10% of the company’s stock.

Key Stories Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations: Intellia reported a smaller-than-expected loss (‑$0.83 vs. consensus ‑$0.99) and revenue of $23.0M (well above estimates), which investors view as proof of commercial progress and operational execution. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Positive Sentiment: Pipeline and regulatory progress: FDA lifted the clinical hold on MAGNITUDE‑2 (nex‑z) and management outlined 2026 launch plans for lonvo‑z (HAE) with mid‑2026 Phase 3 readout expectations and a potential BLA in H2 2026 — milestones that materially de‑risk commercial timelines if achieved. Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Strong cash runway: Intellia ended 2025 with roughly $605M in cash, cash equivalents and marketable securities — a balance that supports continued clinical development and commercial preparation into the near‑term. Intellia Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” and set a $26 price target, signaling notable upside from current levels and providing dealer/retail validation for the bull case. Benzinga
• Neutral Sentiment: Broker estimates: Brookline Capital published a slate of near‑term quarterly EPS forecasts (all negative) but raised long‑range FY2028/FY2029 EPS projections, reflecting high uncertainty today but improved long‑term expectations if pipeline succeeds. MarketBeat Q4 coverage / analyst notes
• Neutral Sentiment: Earnings call detail: Management emphasized commercial readiness for lonvo‑z and clinical plans for nex‑z; transcripts and call highlights are available for deeper review. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Profitability and consensus outlook remain weak: the company still posts large negative margins and the consensus full‑year EPS forecast is deeply negative, keeping NTLA a high‑volatility, binary biotech bet until clinical/commercial milestones are met. MarketBeat: Q4 results and metrics
• Negative Sentiment: Market reaction: despite the positive operational news, the shares are trading lower today — likely reflecting profit‑taking, macro/sector pressure on biotech, and investor caution about execution risk and near‑term losses.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.